
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Trial Design: Identify Blood Pressure Effects Early Demonstrating Biosimilarity CRO/Sponsor: Data Monitoring Committee Users Guide Also in this issue: EU Reshuffling Impacts Pharma "Open Integration" Promise Elusive Assessing Drug-Impaired Driving
about 12 years ago
Ebola Research Requires Flexibility by Sponsors, Regulatorsabout 12 years ago
Is 'Open Integration' Beyond Our Reach?about 12 years ago
Cognitive Guidance for Clinical Drug Trialsabout 12 years ago
All Change for Pharma at the European Commissionabout 12 years ago
Europe Unveils Plan to Standardize Clinical Developmentabout 12 years ago
Implementation and Usage of Data Monitoring Committeesabout 12 years ago
Placement of Trials Increasingly Dispersedabout 12 years ago
ACT coverabout 12 years ago
Demonstrating Biosimilarity: PK Considerationsabout 12 years ago
Blood Pressure Evaluation During Early Phase Trials




